



AstraZeneca 

Leading with health

Sustainability Data Summary 2018

Targets for a more prosperous future

Our sustainability ambition is to lead with health to support healthy people, a thriving planet and an ethical business culture.

Our targets serve as our path forward to achieve sustainable, global growth. The mindset of improving our performance means learning the lessons of the past, building on our prior goals and adapting periodically to achieve a more prosperous future.

We describe our targets and progress for our priorities in this report. We continue to manage other aspects of our strategy, which span many parts of our company.

This is a supplement to our 2018 Sustainability Report, which is available at www.astrazeneca.com/sustainabilityreport.



Access to healthcare Targets

Ambition: Address the global burden of non-communicable diseases (NCDs) through a holistic approach – from prevention to pipeline to treatment

Disease prevention and treatment

Young Health Programme (YHP)

2018 Target

Maintain our YHP in current active markets and expand into three new markets



2018 Update

Our YHP has reached 15 markets

In 2018, it was active in 12 markets and 3 new markets were added

Young Health Programme

2020 Target

Reach 3.5 million young people through YHP



2018 Update

3+ million youth reached (cumulative)

Investments in health systems

People reached

2025 Target

Improve early diagnosis and access to treatment by reaching 25 million people throughout the world through our portfolio of access programmes



2018 Update

12+ million people reached (cumulative)

Healthcare workers trained

2025 Target

Train 75,000 healthcare workers to strengthen health systems throughout the world through our portfolio of Access programmes



2018 Update

35,000+ healthcare workers trained (cumulative)

Bureau Veritas has provided independent external assurance to a limited level for the information on this page as described in the [sustainability letter of assurance](#).



Access to healthcare

Progress

12+ million

people reached by Healthy Heart Africa, Phakamisa and Healthy Lung (cumulative)

Disease prevention and treatment

Young Health Programme	2016	2017	2018
Youth reached (cumulative), million	1.60	2.25	3.01
Active markets	11	12	15
Healthcare workers trained in adolescent health (cumulative)	13,523	14,472	18,591
Peer educators trained (cumulative)	47,330	50,195	50,195

<i>AstraZeneca HealthCare Foundation's Connections for Cardiovascular HealthSM</i> (cumulative) ¹	2016	2017	2018
Total amount given in grants (USD million)	\$21	\$22	\$23
Participants tracked for progress	56,000	58,000 ²	63,000
US-based non-profits funded	49	49	52

Product donation in Cambodia (cumulative)	2016	2017	2018
Women screened and enrolled in the programme	4,577	5,587	6,869
Women diagnosed with breast cancer	753	857	995
Units of medicines administered	166,531	223,046	287,556
Healthcare workers trained	536	565	565

Investments in health systems

People reached by access to healthcare programmes ³ (cumulative, million)	2016	2017	2018
Healthy Heart Africa – cardiovascular screenings	3.000	5.700	9.970
Phakamisa – women reached through early breast cancer detection awareness	1.169	1.402	1.480
Healthy Lung Asia ⁴ – people diagnosed	N/A	0.071	0.531
Healthy Lung Gulf – people diagnosed	N/A	0.001	0.001
Healthy Lung Mexico – people diagnosed	N/A	N/A	0.024
Total people reached (all programmes)	4.169	7.174	12.006

Health facilities activated (cumulative)	2016	2017	2018
Healthy Heart Africa	527	675	701
Healthy Lung Asia ⁴	N/A	152	911
Healthy Lung Saudi Arabia	N/A	N/A	3
Total	527	827	1,615

Access to healthcare

Progress continued

35,000+
healthcare workers trained (cumulative)

Investments in health systems continued

Healthcare workers trained (cumulative)	2016	2017	2018
Healthy Heart Africa	4,006	5,335	5,800
Phakamisa – Physicians and Nurses	600	762	762
Phakamisa – Navigator Volunteers	400	507	523
Healthy Lung Asia	N/A	3,746	26,121
Healthy Lung Gulf	N/A	465	540
Healthy Lung Mexico	N/A	N/A	270
Healthy Lung Saudi Arabia	N/A	N/A	1,540
Total	5,006	10,815	35,556

Affordability

Affordability	2016	2017	2018
People reached by Patient Assistance Programmes (million)	8.6	9.0	9.3
Product donation through Patient Assistance Programmes ⁵ (USD million)	\$466.0	\$401.6	\$686.2

Environment's impact on health

Dunga Beach – Clean Cooking Energy Programme	2016	2017	2018
People screened	N/A	N/A	451
People identified with high blood pressure	N/A	N/A	35
People identified with asthma or COPD symptoms	N/A	N/A	25
Biodigesters (with stoves) installed	N/A	N/A	31

Responsible R&D

Responsible R&D	2016	2017	2018
Projects in the pipeline that use AstraZeneca's precision medicines approach	80%	90%	90%

1 The AstraZeneca HealthCare Foundation is a Delaware (US) not-for-profit corporation and a 501(c)(3) entity, separate from AstraZeneca Pharmaceuticals, organised for charitable purposes including to promote public awareness and education of healthcare issues and support eligible nonprofit organisations in alignment with its mission. The Foundation has received \$30 million in contributions to date from AstraZeneca to support the Connections for Cardiovascular HealthSM programme. All cumulative values are from 2009–15. Self-reported data from Grant Awardees. Some participants have continued in funded programs across multiple grant years and are counted in each year they participated.

2 Number has been updated with data received post report submission.

3 People 'reached' is defined per programme, depending on the operations: Healthy Heart Africa – includes the number of cardiovascular screenings; Phakamisa – includes the number of women reached through early breast cancer detection awareness; Healthy Lung Asia methodology updated from the 2017 – 'people reached' includes only those diagnosed.

4 Healthy Lung numbers revised from the 2017 report.

5 These PAPs use fully-donated product without expectation of payment from the patient for any portion or to access the programme.



Environmental protection* Targets

Ambition: Manage our environmental impact across all our activities and our products

Greenhouse gas reduction

Carbon emissions

2025 Target

Science-based target

- Reduce absolute Scope 1 emissions by 20% against the 2015 baseline
- Reduce absolute Scope 2 emissions by 95% against the 2015 baseline
- Reduce all Scope 3 emissions by 25% per million USD of sales in the same timeframe:
 - Reduce greenhouse gas (GHG) emissions from waste incineration, business air travel, primary distribution (freight and logistics) and critical direct APIs and formulation and packaging (F&P) suppliers (>90% of category spend, energy only) by 20% from 2015 baseline
 - Reduce GHG emissions per device from patient use of inhaler therapy devices from 2015 baseline
 - Improve primary data collection within Scope 3 value chain GHG accounting



2018 Update

Reduced by 6%
Scope 1 emissions

Reduced by 54%
Scope 2 emissions

Reduced by 2%
Scope 3 emissions intensity:

- Increased by 8% absolute Scope 3 emissions from waste incineration, air travel, distribution and targeted suppliers
- Small reduction to 22% Scope 3 primary data collection due to greater spend in an estimated category

Carbon emissions

2025 Target

Maintain operational GHG footprint no greater than 2015 levels by 2025



2018 Update

Operational GHG footprint totalled 1,769,110 tonnes CO₂e, a reduction of 0.4%

Bureau Veritas has provided independent external assurance to a limited level for the information on this page as described in the [sustainability letter of assurance](#).

Energy management

2025 Target

100% renewable power consumption by 2025 globally with an interim target of 100% renewable power in the EU and US by 2020




2018 Update

61% of our total electricity use is sourced or generated from renewable sources

Energy management

2025 Target

Reduce energy consumption by 10% against a 2015 baseline



2018 Update

Energy used was 1,854 GWh, a 3% increase

Vehicle fleet

2025 Target

Achieve a 100% hybrid, plug-in or electric vehicle fleet in Europe, North America and Japan



2018 Update

7% of our fleet in North America, Europe and Japan is a hybrid, plug-in or electric vehicle

Water stewardship

2025 Target

Maintain absolute water use at 2015 baseline levels




2018 Update

Water footprint was 4.01 million m³, an 8% reduction

Waste management

2025 Target

Reduce waste by 10% below the 2015 baseline



2018 Update

Total waste was 31,500 tonnes, a 3% increase from 2015

Product environmental stewardship

2019 Target

Develop a product environmental sustainability index and pilot our approach internally



2018 Update

Developed a framework for the product environmental sustainability index

Resource efficiency

2025 Target

Ensure 90% of active pharmaceutical ingredient (API) syntheses meet resource efficiency targets at launch




2018 Update

50% of API syntheses have met target at launch since the start of the strategy period

Resource efficiency

2020 Target

Develop resource efficiency targets for biologic products



2018 Update

Continued participation in a cross-sector benchmarking through the American Chemical Society Green Chemistry Institute Pharmaceutical Roundtable for a biologic products resource efficiency metric resulting in an external publication. Work to adopt a metric target for internal biologics projects has not progressed as rapidly as planned due to business changes.

Pharmaceuticals in the environment

2025 Target

Lead the industry to manage Pharmaceuticals in the Environment (PIE)



2018 Update

EcoPharmacoVigilance (EPV) programme to monitor product risks post-launch ran through 2017 with no significant risks identified

Co-authored 21 peer-reviewed publications on PIE

100% of API discharges from our sites assessed as safe²

93% of API discharges from suppliers demonstrated as safe²



Environmental protection*

Progress

7%

of our vehicle fleet is hybrid, plug-in or electric, up from <1% in 2017

Greenhouse gas reduction

Carbon emissions (in tonnes CO _{2e}) ¹⁵	2015	2016	2017	2018
Scope 1 ³	318,670*	309,685*	291,694*	301,055
Scope 2 – market based ⁴	348,664	218,770	178,614*	158,987
Scope 3 – operational footprint total	1,109,174	1,155,504*	1,234,739*	1,309,069
Scope 3 – waste incineration	22,483*	24,647*	25,444*	24,327
Scope 3 – freight & logistics	139,150	122,326	116,615	126,068
Scope 3 – business air travel	112,485*	112,485*	112,485*	121,109
Scope 3 – first tier active pharmaceutical ingredient (API), formulation and packaging (F&P) energy (one year in arrears, 90% of spend in each category)	128,119*	96,482	86,393*	162,891
Scope 3 – pMDI use phase	706,936*	799,563	893,802*	874,674
AstraZeneca Operational footprint total (Scopes 1 and 2 and selected Scope 3)	1,776,508	1,683,959*	1,705,047*	1,769,110
Total Scope 3 (all 15 Greenhouse Gas Protocol (GHGP) categories) ⁵	7,184,741	5,813,138*	5,830,380*	6,264,535
Total GHG footprint (million)	7.9	6.3	6.6	6.7

Additional GHG information	2015	2016	2017	2018
tonnes CO _{2e} per million USD of sales	291*	253	260	284
Scope 2 – location based ⁴	285,052	288,210	273,681*	294,906
Scope 3 emissions using primary data	16%	21%*	24%*	22%
Freight (by tonne.km) transport converted from air to sea ⁶	54%	63%	63%	62%

GHG protocol Scope 3 category (tonnes CO _{2e}) ¹⁵	2016	2017	2018
Purchased goods and services	4,078,361*	3,887,601*	4,327,425
Use of sold products	799,563*	893,802*	874,674
Downstream transportation and distribution	317,641*	302,869	296,430
Business travel	137,026*	139,868*	150,821
Upstream transportation and distribution	227,329*	288,406*	297,859
Fuel and energy related (not Scope 1 or 2)	69,795*	65,959*	63,608
Capital goods	88,314	82,935	77,647
Waste generated in operations	25,361	25,743	24,625
End-of-life treatment of sold products	23,597	80,786	89,036
Employee commuting	19,527	20,751	20,751
Upstream leased assets	26,623	29,067	29,067
Downstream leased assets	N/A	12,592	12,592
Total Scope 3 GHGP categories⁴	5,813,138*	5,830,380*	6,264,535

Vehicle fleet	2016	2017	2018
Vehicles with fuel-efficient technology ⁷ – Fleet in North America, Europe and Japan	N/A	<1%	7%
Vehicles with fuel-efficient technology – North America	N/A	N/A	4%
Vehicles with fuel-efficient technology – Europe	N/A	N/A	12%
Vehicles with fuel-efficient technology – Japan	N/A	N/A	16%

Environmental protection*

Progress continued

61%

of our total electricity use is sourced or generated from renewable sources

Greenhouse gas reduction continued

Energy management	2015	2016	2017	2018
Total energy use (MWh)	1,805,236	1,785,357*	1,745,547*	1,853,813
Total renewable energy use – proportion of total energy use	6%	25%	27%	29%
Renewable electricity – imported	14%	58%	63%	69%
Renewable electricity – imported (MWh)	104,107	436,239	461,248*	525,008
Renewable energy power and heat (MWh)	9,568	11,682*	11,537*	14,390
Renewable electricity – on-site solar PV (MWh)	0	0	441	3,358
Total renewable power consumption – RE100 commitment ⁸	13%	53%	57%	61%

Waste management

Waste management	2016	2017	2018
Total waste (tonnes)	31,791*	31,063*	31,500
Non-hazardous waste (tonnes)	22,150*	20,471*	21,344
Hazardous waste (tonnes)	9,641*	10,592	10,156
Total recycling (tonnes)	13,794	14,340	14,390
Recycling as a percentage of total waste	43%	46%	46%

Water stewardship

Water stewardship	2016	2017	2018
Water usage (million m ³)	4.02	3.89	4.01
Chemical oxygen demand – effluent leaving our sites (tonnes)	255.6	283.3	546.7

Water volume by water stress rating for sites with over 10,000 m³ of water per year⁹ (m³)

High-stress rating	N/A	471,577	718,307
Medium-stress rating	N/A	2,001,972	1,650,671
Low-stress rating	N/A	1,312,203	1,542,911

Product environmental stewardship

Resource efficiency	2016	2017	2018
Active pharmaceutical ingredient (API) syntheses meet resource efficiency at launch	100%	50%	50%

Pharmaceuticals in the environment

Safe API discharges	2016	2017	2018
Safe API discharges for AstraZeneca sites ²	100%	100%	100%
Safe API discharges from suppliers ²	92%	90%	93%
Safe API discharge supplier assessments completed	81	80	88

Environmental protection*

Progress continued

Environmental compliance

Compliance summary	2016	2017	2018
Prosecutions ¹⁰	0	0	0
Enforcement actions ¹¹	1	0	1
Regulatory warnings/alerts ¹²	5	6	2
Other environmental compliance matters ¹³	9	9	4
Significant environmental violations ¹⁴	0	0	0
Financial penalties relating to above (USD)	\$1,000	\$0	\$0

Solvent (VOC) consumption and emissions from AstraZeneca sites	2016	2017	2018
Consumption (tonnes)	8,184	3,454	3,511
Emissions (tonnes)	210	173	183

* Regular review of the data is carried out to ensure accuracy and consistency. This has led to changes in the data from previous years. The data quoted in this Sustainability Report and ESG Summary are generated from the revised data.

2 Scope of 51 APIs for which data is available to calculate safe API discharge limits and based on 2017 manufacture.

3 Included in this section are GHGs from direct fuel combustion, process and engineering emissions at our sites and from fuel used in our vehicle fleet.

4 GHGs from imported electricity are calculated using the GHG Protocol Scope 2 Guidance (January 2015) requiring the dual reporting using two emissions factors for each site: market-based and location-based. Location-based factors are the grid average emissions factor for the country (or subregion in the US) where a site is located. Market-based factors are more specific to the site and local energy market, taking account of the residual energy mix a site is sourcing power from and any certified renewable power purchased by a site.

5 See the Scope 3 category for detail.

6 Tonne per km moved.

7 Fuel-efficient technology here refers to hybrid, plug-in or electric vehicles.

8 Proportion of total power consumption including imported, self generated from on-site solar PV and combined heat and power installations.

9 We have developed a standard methodology to assess water risk at every site based on the WRI Aqueduct tool.

10 Prosecution: successful or pending legal action taken in a civil or criminal court against AstraZeneca.

11 Enforcement action: any formal administrative or judicial enforcement proceeding, notices of violation or similar action by a regulator that requires the company to do, or not do, something.

12 Regulatory warning/alert: any formal written warning or alert received from a regulator stating that the company is in violation of an applicable SHE requirement, which if not corrected or repeated, could incur prosecution or enforcement action.

13 Other environmental compliance matter: any less significant environmental compliance matter not included above.

14 Significant environmental violation: those that result in a fine >\$10,000.

15 We implemented a new methodology in early 2019 to calculate Scope 3 emissions, which enables the use of same-year data, rather than reporting some data one year in arrears. This improves accuracy and timeliness and has been applied to Scope 3 metrics from 2015-2018. However, due to timing of the Annual Report publication, the update was not able to be applied to the 2018 Scope 3 metrics. The data shown in this Sustainability Data Summary uses the new methodology and is the most up to date.



Ethics and transparency Targets

Ethical business culture

Business ethics

2025 Target

Maintain 100% of active employees trained on the Code of Ethics



100% of active employees trained in 2018

Business ethics

2020 Target

Ensure AstraZeneca has a 'Speak Up' culture



2018 Update

76% of employees feel we have a 'Speak Up' culture

56.6 instances of non-compliance

with the Code of Ethics per thousand employees in commercial regions

Inclusion and diversity

2022 Target

Reach gender equality in management positions (career level F or higher)



2018 Update

44.6% of women in senior middle management roles or higher

2025 Target

Reach gender equality at the global executive level (career level I and J)



2018 Update

30.2% of women in executive roles

Talent and workforce evolution

Employee satisfaction

2025 Target

Build a strong learning and development culture by 2025 promoting growth opportunities at all levels of our organisation and ensuring a strong leadership pipeline



2018 Update

80% of employees feel there is opportunity for growth and development

80% of senior vacancies filled internally

Employee satisfaction

2025 Target

Ensure AstraZeneca has a highly-engaged workforce and is viewed as a leader in attracting top talent



2018 Update

83% of employees feel that AstraZeneca is a great place to work, up from 81% in 2017

Ambition: Create positive societal impact and promote ethical behaviour in all markets across our value chain

Responsible supply chain

2025 Target

Ensure 100% of spend is assessed through our third-party risk management (3PRM) programme



2018 Update

82% of spend assessed through our 3PRM programme, up from 78% in 2017

2025 Target

75% of all critical direct suppliers are rated 'bronze' or better in our sustainability framework¹



2018 Update

74 critical direct suppliers had an average rating of 72% on their PSCI environmental sustainability assessment

Launched the sustainability framework to obtain an overall baseline in 2019

Workforce wellbeing and safety

2025 Target

Workforce safety: 75% reduction in total injury rate from 2015 baseline



2018 Update

26% reduction in reportable injury rate since 2015

2025 Target

Driver safety: 55% reduction in collisions per million kilometres driven from 2015 baseline




2018 Update

9% reduction in collision rate since 2015

2025 Target

Healthy workforce: 80% of sites/marketing companies have all four Essential Health Activities in place: healthy eating and drinking, tobacco cessation, physical fitness and workplace pressure management



2018 Update

65% of sites promote the four Essential Health Activities

Human rights

2020 Target

Improve the AstraZeneca global biannual human rights survey by using Fair Wage Network data to more robustly assess our performance against local living wage data



2018 Update

100% of countries where we operate were evaluated for local living wage performance

Bureau Veritas has provided independent external assurance to a limited level for the information on this page as described in the [sustainability letter of assurance](#).

Ethics and transparency

Progress

76%

of our employees feel we have a
'Speak Up' culture

Ethical business culture

Business ethics	2016	2017	2018
Active employees trained on Code of Ethics	100%	100%	100%
Percentage of employees who feel we have a 'Speak Up' culture	N/A	N/A	76%
Concerns reported through the company helpline in commercial regions ² (per thousand employees)	9.4	10.4	8.7
Instances of non-compliance with the Code of Ethics in commercial regions ² (per thousand employees)	50.7	41.4	56.6
Corrective actions taken in commercial regions ² (per thousand employees)	56.7	52.3	71.1
Employees terminated or asked to leave due to non-compliance in commercial regions ² (per thousand employees)	6.5	5.1	4.7
Clinical trials transparency (all cumulative)	2016	2017	2018
Publicly available trial summaries	N/A	34	66
Research teams granted access to AZ trials	N/A	25	37
EMA policy 0070 packages published	N/A	3	4
Political donations	2016	2017	2018
Contributions to U.S. national political organisations, state-level political party committees and campaign committees (USD million)	\$1.57	\$1.28	\$1.16

Bioethics

Animal use standards	2016	2017	2018
In-house research ³ (no. of animals)	193,451	131,615	121,823
External contract research (no. of animals)	25,651	28,545	29,853
Total no. of animals	219,102	160,160	151,676
Council for Science and Animal Welfare (C-SAW) Global 3Rs Awards (no. of awards)	3	3	3
Signatory to the Concordat on Openness on Animal Research in the UK	Yes	Yes	Yes
Human biological samples	2016	2017	2018
Human foetal tissue (hFT) supplier assessments	N/A	5	1
hFT suppliers approved	N/A	40%	50%
Active projects using human embryonic stem cells (hESC)	N/A	7	9
hESC projects approved ⁴	N/A	100%	100%
Active projects using hFT	N/A	2	3
hFT projects approved	N/A	25%	33%

Ethics and transparency

Progress continued

44.6%

of women in senior middle management roles or higher

Inclusion and diversity

Inclusion and diversity	2016	2017	2018
Women in Management: All management levels	40.8%	40.7%	41.4%
Women in Management: Career Level F or higher (senior middle management)	43.2%	44.4%	44.6%
Women in Management: Career Level I and J (executive management)	27.9%	28.1%	30.2%
Women representation on Board of Directors	30.0%	42.0%	42.0%
Women representation on SET (Senior Executive Team)	33.0%	36.0%	36.0%
Women representation of AstraZeneca employees	49.9%	50.1%	50.1%
Leadership within country of origin in roles that report to our SET (emerging markets and Japan)	14.5%	13.4%	19.4%

Talent and workforce evolution

Employee satisfaction	2016	2017	2018
Employee perception of the opportunities for personal development and growth	73%	78%	80%
Employees that have at least one quality development discussion with their line manager	82%	83%	82%
Employee belief in our strategy	80%	88%	89%
Employee perception of AstraZeneca as a 'great place to work' survey score	74%	81%	83%
Sustainability engagement survey score ⁵	87%	90%	84%

Talent and workforce evolution

Employee recruitment and retention	2016	2017	2018
Senior vacancies filled by internal candidates	79%	88%	80%
Employees that have a development plan ⁶	93%	66%	52%
Resignation rate of high performers ⁷	6.1%	7.1%	6.6%

Workforce wellbeing and safety

Workforce wellbeing and safety	2016	2017	2018
Total reportable injury rate (per million hours worked) (employees) ⁸	1.57	1.48	1.31
Collisions per million kilometres driven	4.66	4.05	3.74
Occupational illness rate (per million hours worked) (employees) ⁸	0.24	0.30	0.34
Lost time injury rate (per million hours worked) (employees) ⁸	1.09	0.91	0.92
Lost time injury rate (per million hours worked) (construction contractors) ⁹	0.74	1.48	2.21
Fatalities (employees) ⁸	0	0	0
Fatalities (contractors) ⁸	0	0	0
Working days lost due to work-related injury and illness rate ⁸	32.6	46.5	56.2
Sites promoting Essential Health Activities ¹⁰	N/A	67%	65%

Ethics and transparency

Progress continued

82%
of spend assessed through our 3PRM programme, up from 78% in 2017

Human rights

Human rights	2016	2017	2018
Countries that completed the human rights survey ¹¹	106	N/A	106
Countries that have a relationship with trade unions ¹¹	58%	N/A	46%

Responsible supply chain

Responsible supply chain	2016	2017	2018
Total supplier assessments ¹²	8,977	6,139	12,967
Supplier assessments with improvement plans	1,101	273	1,008
Supplier assessment completion rate	96%	95%	90%
High-risk supplier audits	66	41	45
Suppliers failing to meet required standards	40	12	144
Spend assessed through our third-party risk management (3PRM) process	61%	78%	82%
PSCI environmental sustainability assessments completed	N/A	N/A	74
Critical direct suppliers that disclose their energy, waste and water footprint	N/A	N/A	27%

Responsible supply chain

Supply Chain – Environmental footprint for critical direct suppliers ¹³	2016	2017	2018
AstraZeneca manufacturing sites – total waste (thousand tonnes)	26	28	29
API category – total waste (thousand tonnes)	24	29	39
F&P category – total waste (thousand tonnes)	7	4	10
AstraZeneca manufacturing sites – water use (million m ³)	3.2	3.2	3.3
API category – water use (million m ³)	0.3	0.2	1.3
F&P category – water use (million m ³)	0.8	0.6	1.0

Supply chain – CO ₂ footprint for critical direct suppliers ¹³	2015	2016	2017
AstraZeneca manufacturing sites – CO ₂ from energy (thousand tonnes)	388*	301*	263
API category – CO ₂ from energy (thousand tonnes)	35	25	91
F&P ¹⁴ category – CO ₂ from energy (thousand tonnes)	61	61	72



Ethics and transparency

Progress continued

\$38 million

total community investment, sponsorships, partnerships and charitable donations

Philanthropy

Philanthropy	2016	2017	2018
Total community investment, sponsorships, partnerships and charitable donations (not including Patient Assistance) (USD million)	\$39	\$25	\$38.0
Disaster relief product donation (Total US wholesale acquisition cost value in USD million)	\$20.0	\$4.2	\$17.6
Volunteerism hours	20,000	29,095	39,418
Non-profit organisations funded by AstraZeneca	848	919	1,082

Product safety

Product safety	2016	2017	2018
FDA Class I recall	0	1	0
FDA Class II recall	2	2	0
FDA Class III recall	6	10	4
Total FDA recalls	8	13	4
Total FDA observations	1	22	16
Total FDA inspections	3	14	7
Total inspections from all health authorities	33	57	48
Unique health authorities completing inspections	18	21	23

Quality manufacturing

Quality manufacturing	2016	2017	2018
Internal quality audits of AstraZeneca suppliers	461	477	468
Internal quality audits of AstraZeneca sites	36	35	35

- 1 Target applies to suppliers in the Active Pharmaceutical Ingredient (API) and Formulation and Packaging (F&P), and Device categories. All suppliers are in scope for the framework; however, suppliers are only in scope for PSCI environmental sustainability assessments if they cover >90% of our spend per the Sustainability Partner Guide and Framework.
- 2 Adjusted from 2017 numbers to only include our commercial workforce.
- 3 Scope of 2018 data includes some animals used only for breeding.
- 4 100% approval rate reflects self-selection effect that only high-relevance projects with a good justification actually come forward for approval.
- 5 Sustainability engagement question changed slightly from 2016, 2017: 'I am clear on what I need to do in my job to help AstraZeneca achieve its sustainability goals' to 2018: 'I understand how I can contribute to AstraZeneca's sustainability priorities.'
- 6 We updated the measure in 2017 to a more rigorous target: % of employees with career and development items updated during past 12 months. Previous years are not comparable.
- 7 In 2015, we used a different rating system to classify 'high performance'. Number is not comparable to following years.
- 8 The inclusion criteria for injuries and occupational illnesses in the metrics reported here are aligned with the US Occupational Safety and Health Administration (OSHA) Record Keeping Rule. Employees are defined as workers employed according to AstraZeneca terms and conditions and includes temporary or contract staff/contingent workers, who are supervised directly by AstraZeneca personnel. Contractors are defined as persons who provide a service to AstraZeneca and work on AstraZeneca facilities but are employed and managed by another (third party) organisation.
- 9 Construction contractors are defined as workers employed and managed by third-party construction/engineering companies, working on AstraZeneca capital projects.
- 10 Essential Health Activities defined as: healthy eating and drinking, tobacco cessation, physical fitness, workplace pressure management.
- 11 No data in 2017 as the human rights survey is bi-annual.
- 12 Change in methodology from 2017. Number represents the total combining new supplier assessments plus re-assessments of existing suppliers.
- 13 Data collected one year in appears so data in 2017 column actually relates to environmental footprint in 2016 and so on. Covering >90% spend.
- 14 F&P is formulation and packaging.